Prof. Rolf G. Werner is Honorary Senator and Professor of the University of Tübingen. With his own PharmaConsulting company he performed conceptual design of more than 10 large-scale GMP manufacturing plants and implemented advanced manufacturing technologies for empowered protein and nucleic acid therapeutics as well as established corporate strategies in the biopharmaceutical industries.
Prof. Rolf G. Werner holds a Ph.D. Degree and a Habilitation for his professorship from the University of Tübingen. He did his sabbatical at Max-Plank Institute for Molecular Genetics in Berlin and his postdoc at the Massachusetts Institute of Technology in Cambridge, USA.
In his more than 35 years of experiences in the Pharmaceutical Industry at Boehringer Ingelheim in top leading positions with global responsibilities, he identified new antibiotics and optimized antimicrobial lead compounds. As Corporate Senior Vice President of the Biopharmaceutical Division at Boehringer Ingelheim, he managed the collaboration with Genentech Inc. for the development, manufacturing, and registration of the first, genetically engineered, human therapeutic protein, expressed in mammalian cell culture: tissue plasminogen activator (t-PA), which is still the treatments of choice for myocardial infarction and stroke. He designed the first and largest stainless-steel GMP plants in 6 x 15000 L scale in Europe within 18 months from groundbreaking to operation. He established the CDMO business with more than € 1bn sales at the biopharmaceutical sites in Germany, Austria, the USA, and China.
His achievements as a pioneer in biologics have been recognized with the honorary Ph.D. of the University Chiang Mai, Thailand, the Prize of the City of Vienna, Austria, the Hangzhou Qian Jiang Distinguished Expert in Biotechnology, and the Chinese National Foreign Expert.
